AEON Biopharma, Inc.

For the period ended Mar 31, 2025. Filed May 14, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 14, 2025

AEON$0.18-1.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

(in thousands, except share data and par value amounts)


· · March 31, · · December 31, ·
· 2025 · 2024 ·
· · (Unaudited) · · ·
ASSETS · · ·
Current assets: · · ·
Cash and cash equivalents	$10,446	$13
Prepaid expenses and other current assets	1,875	1,577
Total current assets	12,321	1,590
Property and equipment, net	220	235
Operating lease right-of-use asset	1,229	1,288
Other assets	29	29
Total assets	$13,799	$3,142
LIABILITIES AND STOCKHOLDERS' DEFICIT
Current liabilities:
Accounts payable	$2,437	$5,910
Accrued clinical trials expenses	3,015	3,571
Accrued compensation	429	1,068
Other accrued expenses	2,759	3,600
Total current liabilities	8,640	14,149
Convertible notes at fair value, including related party amount of $13,320 and $11,689, at March 31, 2025 and December 31, 2024, respectively	13,320	11,689
Operating lease liability	1,083	1,145
Warrant liability	2,026	1,187
Contingent consideration liability	53	3,541
Total liabilities	25,122	31,711
Commitments and contingencies
Stockholders’ Deficit:
Class A common stock, $0.0001 par value; 1,040,000,000 and 500,000,000 shares authorized at March 31, 2025 and December 31, 2024, and 10,538,615 and 555,511 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively	9	4
Additional paid-in capital	411,170	403,024
Accumulated deficit	(422,502)	(431,597)
Total stockholders' deficit	(11,323)	(28,569)
Total liabilities and stockholders' deficit	$13,799	$3,142

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.